Rofecoxib, selective COX-2 inhibitors and cardiovascular risk

被引：0
|
作者：
Dhaun, N. [1 ]
Maxwell, S. R. J. [1 ]
Webb, D. J. [2 ]
机构：
[1] Univ Edinburgh, Therapeut & Pharmacol, Edinburgh, Midlothian, Scotland
[2] Univ Edinburgh, Clin Pharmacol Unit, Edinburgh, Midlothian, Scotland
来源：
JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH | 2005年 / 35卷 / 02期
关键词：
Cardiovascular risk; Rofecoxib; selective COX-2 inhibitors;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：101 / 103
页数：3
相关论文
共 50 条
  • [21] Risk of hyperkalemia associated with selective COX-2 inhibitors
    Aljadhey, Hisham
    Tu, Wanzhu
    Hansen, Richard A.
    Blalock, Susan
    Brater, Craig
    Murray, Michael D.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 (11) : 1194 - 1198
  • [22] Selective COX-2 inhibitors
    Parnham, MJ
    DRUG NEWS & PERSPECTIVES, 1997, 10 (03) : 182 - 187
  • [23] Selective COX-2 inhibitors and risk of myocardial infarction
    Krötz, F
    Schiele, TM
    Klauss, V
    Sohn, HY
    JOURNAL OF VASCULAR RESEARCH, 2005, 42 (04) : 312 - 324
  • [24] Selective COX-2 inhibitors
    Lloyd, AW
    DRUG DISCOVERY TODAY, 1997, 2 (03) : 122 - 122
  • [25] Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation
    R. M. Pinheiro
    J. B. Calixto
    Inflammation Research, 2002, 51 : 603 - 610
  • [26] Selective COX-2 inhibitors
    Pasero, C
    McCaffery, M
    AMERICAN JOURNAL OF NURSING, 2001, 101 (04) : 55 - 56
  • [27] Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis
    Watson, DJ
    Harper, SE
    Zhao, PL
    Quan, H
    Bolognese, JA
    Simon, TJ
    ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (19) : 2998 - 3003
  • [28] Celecoxib and rofecoxib - The role of COX-2 inhibitors in dental practice
    Moore, PA
    Hersh, EV
    JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 2001, 132 (04): : 451 - 456
  • [29] Changes in the characteristics of patients prescribed selective Cox-2 inhibitors after the 2004 withdrawal of rofecoxib
    Setakis, Efrosim
    Leufkens, Hubert G. M.
    van Staa, Tjeerd P.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S218 - S219
  • [30] Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk
    Motsko, Stephen P.
    Rascati, Karen L.
    Busti, Anthony J.
    Wilson, James P.
    Barner, Jamie C.
    Lawson, Kenneth A.
    Worchel, Jason
    DRUG SAFETY, 2006, 29 (07) : 621 - 632
12345